跳至主要内容
临床试验/NCT02325817
NCT02325817已完成不适用

A Multicenter, Superior, Randomized Controlled Clinical Trial to Observe the Safety and Efficacy of Bingo Drug-eluting Balloon vs. Yinyi Balloon Dilatation Catheter in the Treatment of Patients With Bifurcation Stenosis Lesions of Coronary Artery

Yinyi(Liaoning) Biotech Co., Ltd.1 个研究点 分布在 1 个国家目标入组 222 人开始时间: 2014年12月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
222
试验地点
1
主要终点
Target lesion Stenosis (diameter, %)

研究概览

简要总结

The purpose is to observe and evaluate the safety and efficacy of Bingo drug-eluting balloon in the treatment of patients with bifurcation lesions of coronary artery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or non-pregnant female ages 18-80 years old
  • Patients with asymptomatic myocardial ischemia symptom, stable or unstable angina pectoris or old myocardial infarction
  • Patients with bifurcation lesions of coronary artery observed by angiography.
  • The main branch of the vessels are suitable for PCI and stent therapy, and the side branch are intended to implement the kissing dilatation without considering dual stent implantation.
  • De Novo bifurcation lesions and diameter stenosis are not less than70%;
  • Referenced vessel diameters range from 1.25mm to 5.0mm, and lesions range are not more than 40mm
  • Residual stenosis are not more than 50% after predilatation;
  • Patients who understand the purpose of this trial, voluntary and sign informed consent.

排除标准

  • Heavily calcified lesions which cannot be dalatated successfully, and the lesions which are not suitable by balloon angioplasty
  • Left main coronary artery lesions without protection or related bifurcation lesions
  • Patients with severe heart failure symptoms (above NYHA III) or Left ventricular ejection fraction (LVEF) below 35% (ultrasound or left ventricular angiography)
  • Impairment of the renal function preoperative: Serum creatinine above 2.0mg/dl;
  • Patients with hemorrhagic tendency, the history of active digestive ulcers, the history of subarachnoid hemorrhage cerebral hemorrhage, antiplatelet and anticoagulant therapy contraindication and unable to anticoagulant therapy;
  • Patients who are allergic to aspirin, ticagrelor, clopidogrel, ticlopidine, heparin, contrast agent and paclitaxel, and cannot 1-year tolerate dual antiplatelet therapy (aspirin + clopidogrel or ticagrelor)
  • Patients whose expected lives are less than 1 year;
  • Patients who are considered to have poor compliance and cannot complete the trial in accordance with requirements.
  • In-stent restenosis lesions
  • Patients who are enrolled in this trial and need stent therapy due to vascular laceration or severe stenosis, and those patients are calculated as fall off cases.

研究组 & 干预措施

Drug-eluting balloon

Experimental

Treat the side branch of bifurcation lesion with drug-eluting balloon

干预措施: Drug-eluting balloon (Device)

Uncoated balloon

Active Comparator

Treat the side branch of bifurcation lesion with uncoated balloon

干预措施: Uncoated ballloon (Device)

结局指标

主要结局

Target lesion Stenosis (diameter, %)

时间窗: 9 months

次要结局

  • All-cause death(1, 6 and 9 months)
  • Cardiac death(1, 6 and 9 months)
  • TLR(1, 6 and 9 months)
  • TVR(1, 6 and 9 months)
  • TLF(1, 6 and 9 months)
  • MACCE(1, 6 and 9 months)
  • Non-fatal MI, thrombosis(1, 6 and 9 months)
  • Thrombosis(1, 6 and 9 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验